Kye Pharmaceuticals seeks Health Canada approval for DMD drug

MISSISSAUGA, ON - Kye Pharmaceuticals Inc. has submitted a New Drug Submission (NDS) to Health Canada for AGAMREE® (vamorolone), a potential treatment for Duchenne muscular dystrophy (DMD), the company announced today. If approved, AGAMREE® would be the first and only therapy sanctioned in Canada for DMD, a rare and progressive neuromuscular disorder. The development comes as pharmaceutical companies in the rare disease space continue showing strong market performance, according to InvestingPro analysis of the sector.

The submission follows the drug's approval in the United States in 2023 and the European Union in early 2024. Health Canada has granted AGAMREE® a priority review, which could lead to marketing authorization before the end of 2025. This expansion aligns with the broader industry trend of geographic diversification in rare disease treatments.

Vamorolone's priority review has been positively received by national patient organizations, highlighting the absence of approved treatments for DMD in Canada and the potential benefits AGAMREE® could bring to patients. The Canadian Neuromuscular Disease registry estimates over 800 boys and young men live with DMD in Canada.

AGAMREE®'s mechanism of action is based on modifying activity on glucocorticoid and mineralocorticoid receptors, which may offer comparable efficacy to traditional steroids with a potentially better-tolerated side effect profile. In the VISION-DMD study, AGAMREE® met the primary endpoint and showed a favorable safety and tolerability profile.

Kye Pharmaceuticals, a Canadian specialty pharmaceutical company, focuses on novel prescription medicines for various therapeutic areas, including rare diseases. The company has partnered with Catalyst Pharmaceuticals, which holds a commercial presence in the U.S. and seeks global expansion. According to InvestingPro data, Catalyst demonstrates strong financial fundamentals with an impressive 85.6% gross profit margin and 23.5% revenue growth in the last twelve months. The company maintains excellent financial health with an InvestingPro Financial Health Score of 4.06 out of 5, suggesting robust operational efficiency. For deeper insights into the pharmaceutical sector and access to comprehensive analysis of over 1,400 stocks, including Catalyst Pharmaceuticals' detailed Pro Research Report, consider exploring InvestingPro's extensive database and analytical tools.

The information for this article is based on a press release statement.

In other recent news, Catalyst Pharmaceuticals has reported strong financial results for the fourth quarter and full year of 2024, with total revenue reaching $491.7 million, surpassing their guidance range. The company also provided a revenue forecast for 2025, projecting between $545 million and $565 million, driven by robust sales of their products, including AGAMREE and FIRDAPSE. In the fourth quarter of 2024, Catalyst achieved an earnings per share (EPS) of $0.70, significantly exceeding the expected $0.32, and revenue of $141.8 million, surpassing forecasts. Stephens analyst Sudan Loganathan raised the price target for Catalyst Pharmaceuticals to $40, maintaining an Overweight rating, following the company's impressive financial performance. Additionally, Catalyst announced that its sub-licensee, Kye Pharmaceuticals, received acceptance from Health Canada for the New Drug Submission of AGAMREE, which has been granted Priority Review. This development could lead to AGAMREE becoming the first authorized treatment for Duchenne muscular dystrophy in Canada. Catalyst's strong growth narrative is further supported by potential plans to in-license an accretive asset within the year.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.